By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Miraculins today said that it has successfully completed a two-part ISO certification audit conducted by the BSI Group.

The Winnipeg, Manitoba-based biomarker-based diagnostics firm said that the audit recommended that the firm receive ISO 13485 certification. The company said the certification is a "critical regulatory and business plan milestone" as heads toward commercial launch of its PreVu Non-Invasive Skin Cholesterol test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.